Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Eric Van Cutsem, Prianka Singh, James M. Cleary, Ronan Joseph Kelly, Markus H. Moehler, Jaroslaw Kuzdzal, Guillermo Mendez, Satoru Motoyama, Elena Elimova, Cecile Grootscholten, Xiaowu Sun, Fiona Taylor, Rachael Lawrance, Brad Padilla, Alejandro Moreno-Koehler, Jenny Zhang, Steven I. Blum, Jaffer A. Ajani
Institutions: KU Leuven, Bristol-Myers Squibb (United States), Dana-Farber Cancer Institute, Baylor University Medical Center, University Medical Center of the Johannes Gutenberg University Mainz, Jagiellonian University, John Paul II Hospital, Favaloro Foundation, Akita University Hospital, Princess Margaret Cancer Centre, The Netherlands Cancer Institute, Adelphi Group (United Kingdom), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3124600345